National Cancer Institute; Amended Notice of Meeting

---
identifier: "/us/fr/2017-03274"
source: "fr"
legal_status: "authoritative_unofficial"
title: "National Cancer Institute; Amended Notice of Meeting"
title_number: 0
title_name: "Federal Register"
section_number: "2017-03274"
section_name: "National Cancer Institute; Amended Notice of Meeting"
positive_law: false
currency: "2017-02-21"
last_updated: "2017-02-21"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2017-03274"
document_type: "notice"
publication_date: "2017-02-21"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
fr_citation: "82 FR 11236"
fr_volume: 82
---


#  National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the President's Cancer Panel, March 27, 2017, 9:00 a.m. to March 28, 2017, 1:00 p.m., Kimpton Hotel Palomar, Philadelphia, PA 19103 which was published in the *Federal Register* on February 1, 2017, 82 FR 8944.

This meeting notice is amended to change the ending date and time from March 28, 2017 at 1:00 p.m. to March 27, 2017 at 4:30 p.m. The agenda has also been amended as follows: “Welcome and Introductions; Session 1: The Pricing and Payment Landscapes—Framing the Issues—1 and 2; Session 2: Cancer Drug Value/Intervention Framework; Public Comment; Session 3: High-Cost/High Value Drugs; Session 4: High-Cost/Modest Value Drugs; Public Comment; Wrap-Up and Next Steps.” The meeting is open to the public.

Dated: February 14, 2017.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.